ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.
Latest news
ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01
Science & Medicine
Read more 
ImCheck Therapeutics Appoints Dr. Loui Madakamutil, Noted Expert in Immunology and Autoimmune Diseases, as Chief Scientific Officer
Leadership & Corporate
Read more Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response
Science & Medicine
Read more 
STAY IN TOUCH WITH OUR LATEST NEWS
Subscribe to receive our press releases and related news